Navigation Links
Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

annual relapse rate prior to entry, versus patients who received the 20 mg dose (62 percent reduction). The time to the first relapse was significantly delayed from 80 days in the 20 mg group to 213 days in the 40 mg group (p = 0.0367). The overall safety profile was similar to that of the 20 mg dose. Some features of injection site reactions and immediate post-injection reactions were more common.

About Multiple Sclerosis

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over two million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About COPAXONE(R)

COPAXONE(R) is indicated for the reduction of the frequency of relapses in RRMS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, a lump or an indentation at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 phar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) and ... have entered into a clinical trial collaboration to evaluate ... immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... The planned study will assess the combination as a ... The Phase I study is expected to establish the ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... U.S. Food and Drug Administration today advised consumers ... not to use the product. FDA warns that ... active pharmaceutical ingredient sibutramine, a prescription-only drug which ... the product label and could harm consumers, especially ...
... 8 Synapse Biomedical Inc ... U.S. Food and Drug Administration (FDA) designation of the ... Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis ( ... experiencing chronic hypoventilation and has now submitted for Humanitarian ...
Cached Medicine Technology:FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 3Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 4
(Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... is giving patients a long-lasting impression on what ... provider of VisitandCare.com is on a mission to revolutionize ... cosmetic dentistry with a high-class Wellness & Spa. ... of the world’s most successful medical tourism agencies ...
(Date:5/29/2015)... May 29, 2015 As spring has ... Metro series outdoor saunas have increased in popularity as ... and work at summer cottages. While a perennial ... in summer projects a few weeks earlier than usual. ... with smaller lot sizes tend to prefer the Patio ...
Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... therapy (ECT) helps patients with severe depression who don't ... often in the earlier stages of the illness, ... ,"Electroconvulsive therapy has been shown to be ... persistent and severe depression, bipolar disorder, and schizophrenia," writes ...
... sudden outbreak of disease has claimed a tenth of Idahos ... fish food and labor. , The outbreak of ... in southwestern Idaho- the state Department of Fish and Game ... the region and official say that it probably resulted when ...
... Monday opposed introduction of sex education in Kashmir schools ... ,Addressing a media conference here, Asiya Andrabi, the DeM ... nefarious Indian designs to perpetuate obscenity and vulgarity in ... schools." ,Andrabi, branded as a hardliner, said ...
... in regard to doctor-patient ratio in various State Government ... varies from case to case depending upon various factors ... of patient-care required i.e. indoor/outdoor. According to the Medical ... works out to 1:1722. ,The patient ...
... company Advanced Cell Technology, is obviously thrilled with ... repair arteries and regenerate blood. , According to ... proceed on to hearts and arteries of ... have devised a straightforward way to make blood vessel precursor ...
... are 73557. There are 22273 numbers of doctors at ... on March 2006. As on 1.1.2007, total numbers of beds ... beds are available in urban government hospitals including Community Health ... of CHCs are located in government buildings. As on March ...
Cached Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2Health News:Hemangioblasts Aiding Eye Damage Repair 2
... Disc is a Hand Assisted Laparoscopic Surgery ... the surgeons hand may facilitate the procedure, ... has applications in colorectal, urological and general ... extracorporeal extension of pneumoperitoneum and abdominal access ...
... SleepStyle 200 series offers a range ... models. The design delivers therapy to ... features promote results in commercial and ... strongest differentiator in the SleepStyle 200 ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... S6 Lightweight II CPAP has sound ... that maintains consistent pressure. The backlit ... the settings easy, and the interface ... adjustments is simple. This CPAP device ...
Medicine Products: